The EACH/PIC Coalition submitted a comment letter to the Maryland PDAB, providing input on the proposed UPL frameworks for Ozempic and Trulicity, which were considered by the board during their […]
The EACH/PIC Coalition submitted comments to the Oregon PDAB in advance of their February meeting. The letter provided feedback to the board on the finalization of their 2025 cost review
January 28, 2026 On January 27, 2026, the Centers for Medicare and Medicaid Services (CMS) announced the next round of 15 medications subject to Medicare negotiation. More details are available
The EACH/PIC Coalition submitted written testimony to the Virginia Senate Commerce and Labor Committee ahead of consideration of S.B. 271. The letter urged the committee to oppose or amend legislation
The EACH/PIC Coalition submitted a comment letter to the Maryland PDAB providing input on their policy review and consideration of UPL frameworks for Ozempic and Trulicity. The letter stated: “We
The EACH/PIC Coalition submitted written testimony to the Virginia Senate Education and Health Committee ahead of consideration of S.B. 271. The letter urged the committee to oppose or amend legislation
The EACH/PIC Coalition submitted comments to the Oregon PDAB in advance of their January meeting. The letter urged caution as the board makes finalizes its 2025 drug review and provided
The EACH/PIC Coalition sent letters to leadership and members of the House Committee on Energy and Commerce Subcommittee on Health and House Committee on Ways and Means ahead of their
January 13, 2026 Legislation that would establish a Prescription Drug Affordability Board in Virginia with authority to set upper payment limits was reintroduced by Delegate Delaney on January 12th. In
The EACH/PIC Coalition submitted comments to the Colorado PDAB on the proposed recommendations for engaging patients in the cost review process developed through the PDAAC-led stakeholder workgroup. The letter urges
